Who
Daniel Lochner
Chief Financial Officer
Company insider
Files Form 4 as: Chief Financial Officer, Tectonic Therapeutic; Chief Financial Officer, Oyster Point Pharma.
In numbers
- Trades disclosed
- 50
- Buys
- 3
- Sells
- 0
- Bought
- $610K
- Sold
- $0
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 4 Nov 2019
- Last trade
- 25 Sep 2026
- Last filed
- 2 Oct 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 25 Sep 2026filed 2 Oct 2026 | TECX Tectonic TherapeuticBiotechnology | SEC FORM 4 Code F | $12K520 at $23.67 | filing |
| 3 Sep 2026filed 8 Sep 2026 | TECX Tectonic Therapeuticoption or derivative · Biotechnology | SEC FORM 4 Code A | —24,250 at $0.00 | filing |
| 3 Sep 2026filed 8 Sep 2026 | TECX Tectonic Therapeuticoption or derivative · Biotechnology | SEC FORM 4 Code A | —24,250 at $0.00 | filing |
| 11 Jun 2026filed 12 Jun 2026 | TECX Tectonic Therapeuticoption or derivative · Biotechnology | SEC FORM 4 Code A | —7,500 at $0.00 | filing |
| 11 Jun 2026filed 12 Jun 2026 | TECX Tectonic Therapeuticoption or derivative · Biotechnology | SEC FORM 4 Code A | —7,500 at $0.00 | filing |
| 4 Mar 2026filed 5 Mar 2026 | TECX Tectonic TherapeuticBiotechnology | SEC FORM 4 Code A | —26,500 at $0.00 | filing |
| 4 Mar 2026filed 5 Mar 2026 | TECX Tectonic Therapeuticoption or derivative · Biotechnology | SEC FORM 4 Code A | —24,250 at $0.00 | filing |
| 4 Mar 2026filed 5 Mar 2026 | TECX Tectonic Therapeuticoption or derivative · Biotechnology | SEC FORM 4 Code A | —24,250 at $0.00 | filing |
| 4 Mar 2026filed 5 Mar 2026 | TECX Tectonic TherapeuticBiotechnology | SEC FORM 4 Code A | —26,500 at $0.00 | filing |
| 10 Feb 2026filed 11 Feb 2026 | TECX Tectonic TherapeuticBiotechnology | SEC FORM 4 Bought | $130K6,000 at $21.61 | filing |
| 10 Feb 2026filed 11 Feb 2026 | TECX Tectonic TherapeuticBiotechnology | SEC FORM 4 Bought | $130K6,000 at $21.61 | filing |
| 4 Feb 2026filed 10 Feb 2026 | TECX Tectonic TherapeuticBiotechnology | SEC FORM 4 Code F | $48K2,077 at $23.22 | filing |
| 4 Feb 2026filed 10 Feb 2026 | TECX Tectonic TherapeuticBiotechnology | SEC FORM 4 Code F | $48K2,077 at $23.22 | filing |
| 25 Sep 2025filed 29 Sep 2025 | TECX Tectonic Therapeuticoption or derivative · Biotechnology | SEC FORM 4 Code A | —9,860 at $0.00 | filing |
| 25 Sep 2025filed 29 Sep 2025 | TECX Tectonic TherapeuticBiotechnology | SEC FORM 4 Code A | —5,430 at $0.00 | filing |
| 5 Feb 2025filed 7 Feb 2025 | TECX Tectonic TherapeuticBiotechnology | SEC FORM 4 Bought | $250K4,617 at $54.14 | filing |
| 4 Feb 2025filed 6 Feb 2025 | TECX Tectonic Therapeuticoption or derivative · Biotechnology | SEC FORM 4 Code A | —32,862 at $0.00 | filing |
| 4 Feb 2025filed 6 Feb 2025 | TECX Tectonic TherapeuticBiotechnology | SEC FORM 4 Code A | —18,074 at $0.00 | filing |
| 20 Jun 2024filed 24 Jun 2024 | TECX Tectonic Therapeuticoption or derivative · Biotechnology | SEC FORM 4 Code A | —118,000 at $0.00 | filing |
| 3 Jan 2023filed 4 Jan 2023 | Oyster Point Pharmaoption or derivative | SEC FORM 4 Code D | —300,000 | filing |
News
No headline names them, or the companies they trade most, lately.